KYPROLIS (carfilzomib) for Injection Menu

Introducing Support, Simplified

See How We Can Help Your Patients

Offering the tools, information, and support for Amgen products
that make a difference for you and your patients

AMGEN REIMBURSEMENT SPECIALISTS

Connect with an Amgen Reimbursement Counselor or schedule a visit with a Field Reimbursement Specialist.

PATIENT RESOURCE GUIDE

Find co-pay and reimbursement resources for patients with different kinds of insurance, or no insurance at all.

BENEFIT VERIFICATION

Submit, store and retrieve benefit verifications for all your patients currently on an Amgen product.

Amgen Assist 360™ Nurse Ambassadors

A Nurse Ambassador is a single point of contact that helps patients and caregivers find the resources that are most important to them so that they can stay focused on their treatment. Nurse Ambassadors are there to support, not replace your treatment plan.*

CO-PAY AND REIMBURSEMENT ASSISTANCE

Help patients with insurance benefit verification and put them in touch with programs that may help them afford their prescribed medication, such as Amgen FIRST STEP™ for commercially insured patients, or independent nonprofit organizations.

HELP FINDING TRANSPORTATION AND LODGING ASSISTANCE

Refer patients needing assistance with travel related to their therapy to independent nonprofit organizations that may provide help with gas, tolls, parking, airfare, and lodging.

REFERRALS TO RESOURCES FOR DAY-TO-DAY LIVING

Help patients get in touch with independent nonprofit organizations that may provide community resources, local support groups, and counseling services.

CO-PAY AND REIMBURSEMENT ASSISTANCE

Help patients with insurance benefit verification and put them in touch with programs that may help them afford their prescribed medication, such as Amgen FIRST STEP™ for commercially insured patients, or independent nonprofit organizations.

HELP FINDING TRANSPORTATION AND LODGING ASSISTANCE

Refer patients needing assistance with travel related to their therapy to independent nonprofit organizations that may provide help with gas, tolls, parking, airfare, and lodging.

REFERRALS TO RESOURCES FOR DAY-TO-DAY LIVING

Help patients get in touch with independent nonprofit organizations that may provide community resources, local support groups, and counseling services.

*Amgen Assist 360™ is not intended to provide medical advice, case management services, or replace a patient’s treatment plan. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Provided through independent nonprofit patient assistance programs; program eligibility is based on the nonprofit's criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Important Safety Information

Cardiac Toxicities

  • New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of KYPROLIS. Some events occurred in patients with normal baseline ventricular function. Death due to cardiac arrest has occurred within one day of KYPROLIS administration.
  • Monitor patients for clinical signs or symptoms of cardiac failure or cardiac ischemia. Evaluate promptly if cardiac toxicity is suspected. Withhold KYPROLIS for Grade 3 or 4 cardiac adverse events until recovery, and consider whether to restart KYPROLIS at 1 dose level reduction based on a benefit/risk assessment.
  • While adequate hydration is required prior to each dose in Cycle 1, monitor all patients for evidence of volume overload, especially patients at risk for cardiac failure. Adjust total fluid intake as clinically appropriate in patients with baseline cardiac failure or who are at risk for cardiac failure.
  • Patients ≥ 75 years, the risk of cardiac failure is increased. Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction, conduction abnormalities, angina, or arrhythmias may be at greater risk for cardiac complications and should have a comprehensive medical assessment (including blood pressure and fluid management) prior to starting treatment with KYPROLIS and remain under close follow-up.

Acute Renal Failure

Tumor Lysis Syndrome

Pulmonary Toxicity

Pulmonary Hypertension

Dyspnea

Hypertension

Venous Thrombosis

Infusion Reactions

Hemorrhage

Thrombocytopenia

Hepatic Toxicity and Hepatic Failure

Thrombotic Microangiopathy

Posterior Reversible Encephalopathy Syndrome (PRES)

Embryo-fetal Toxicity

Adverse reactions

Please see full Prescribing Information.

Indications